February 29, 2016
News last week from the Conference on Retroviruses and Opportunistic Infections (CROI)
in Boston was dominated by new efficacy data from two vaginal ring trials that have implications for HIV prevention for women. Our take on it is here
, along with a special page
with more background than we could squeeze into a blog post. But, the CROI buzz wasn’t all about vaginal rings, and this update provides some ways to hear more about what happened last week and what it all means.
Post-CROI Webinar Series
The first in a series of post-CROI webinars that will cover a range of topics over the next couple of months is on Tuesday. This webinar, which will explore the ring results with advocates and researchers, is Tuesday, March 1, 8–9am US ET
for the time in your area). Register here
. And stay tuned for details about the additional webinars in the series!
In addition to lots of media reports and publications, our colleagues at NAM/aidsmap
, The Body
all provided in-depth coverage of the myriad studies presented in oral abstract sessions, posters and more. Check out the hyperlinks above for comprehensive coverage.
CROI Program and Webcast
CROI provides a number of ways to review what happened in Boston: check out the full program
; taped playbacks of press conferences
; webcasts of all sessions
; and electronic posters
will be available a week after the conference. There was a wealth of information on a wide range of topics, but here is a selection of sessions and presentations you might want to explore:
Lifetime HIV risk in the US:
New data from the US Centers for Disease Control and Prevention (CDC) projected that 1 in 2 black gay men could be diagnosed with HIV in their lifetime
. That number is 1 in 4 for Latino gay men and 1 in 49 for African American women. The figures for white men and women are far lower. These data highlight the ways that race impacts access to healthcare at every point in the treatment cascade. They suggest an urgent need to provide prevention including PrEP at a wider scale and with messages and programs that are community-designed and owned. They also provide another opportunity to examine the ways that alarming statistics do and do not advance a structural analysis of the problems and solutions to public health issues. As one article highlighted
—individual risk calculations can lay the burden on individuals to change behavior when the drivers of risk are systemic, embedded and often out of individual control.
PrEP in the Real-er World
: There was a lot of data on oral PrEP that, as expected, added layers to understanding of what the strategy is, and what it can and cannot do. It started with a presentation
by Keith Green (University of Chicago) on Engaging Young Men of Color in Community HIV Prevention Studies and later Darrell Wheeler (SUNY Albany) presented an important PrEP study
in Black MSM (HPTN 073), which showed that a culturally anchored “client-centered care coordination” model (C4) was important to getting men into and supported in a PrEP program. Other data gave some insight into additional components of PrEP programming and messaging. Presentations included findings that PrEP use can have a limited impact on renal function
—as it can in people living with HIV who use TDF/FTC as part of treatment; an update from a New York City PrEP project
where rates of sexually transmitted infections among PrEP users suggest that routine screening—at every clinic visit—should be the norm; and finally, a presentation of HIV infection in an adherent PrEP user
who acquired TDF/FTC-resistant HIV. Each of these presentations raises concerns—and thebody.com
has developed an excellent resource on the HIV-resistance data
—but none are insurmountable or even surprising. Piloting PrEP in the real world is the only way to find out how best do deliver, message and monitor this new strategy to all populations at risk.
Long-Acting Injectables for Treatment—and Prevention:
Antiretrotival treatment options took a step forward with the first injectable treatment option. 91% of patients in a study
of the 8-week long-acting injectable cabotegravir and rilpivirine combination regimen maintained virological suppression and also expressed satisfaction with this new option in a new study
. Both cabotegravir and rilpivirine
are also being explored separately as PrEP agents. Marty Markowitz (Aaron Diamond AIDS Research Center) presented results from the Phase IIa ÉCLAIR study
that examined the safety and pharmokinetics of cabotegravir in HIV-uninfected men, setting the stage for a future Phase III efficacy trial.
Turning Targets into Treatment:
A full abstract-driven session was devoted to Getting to 90/90/90
and included Tendani Gaolathe (Botswana Harvard AIDS Institute Partnership) presenting
on how Botswana is approaching the 90-90-90 goal, getting to 83% (testing), 87% (on treatment) and 96% (virally suppressed) representing an overall level of viral suppression of 70% as compared to the 73% goal of the 90-90-90 goals. Factors predictive of not being virally suppressed included youth, male gender, single status and, interestingly, higher education level. At the same time, there was a presentation
on how Malawi is using its Option B+ rollout to prepare for universal treatment. The challenges of Option B+ could be seen in the 25% drop off in post-partum adherence by women after six months. And in a separate session, Helen Ayles (London School of Hygiene & Tropical Medicine) presented Missing But in Action: Where Are the Men?
raising an emerging discussion of how to reach HIV-positive men with treatment programs. Strategies suggested include taking testing outside antenatal clinics and engagement through men’s clubs and even bars. While reaching these men is important, it remains critical that treatment for all who need it remain a focus.
Broadly Neutralizing Antibodies Expand Out of the Vaccine Field:
John Mascola (Vaccine Research Center) opened the first full day of the conference with a plenary on broadly neutralizing antibodies
for prevention and treatment. See aidsmap's excellent coverage
. Mascola described plans for the Antibody-Mediated Protection (AMP) prevention trial
, which is due to start in a few months, and the first treatment studies of the bNAb VRC01 in people on ART. Later in the conference, Ken Mayer (Fenway Health) presented data
from the HVTN 104 Phase 1 study of the VRC01 antibody for prevention.
Rectal Microbicides Well Received:
Ross Cranston (MTN) presented data from MTN 017
, the first Phase II rectal microbicide gel study—it showed no safety risk and both adherence and acceptability were high. The open-label trial looked at a rectal formulation of tenofovir gel inserted via vaginal applicator, comparing its daily use with event-driven (used before and after sex) use. A third study regimen included the use of daily oral Truvada as PrEP. All 195 MSM and transgender women cycled through each of the three regimens for eight weeks. Adherence feedback was provided to participants through daily texts, returned applicators and real-time drug levels reporting. This contributed to high adherence across all study regimens. Overall preference favors Truvada as PrEP slightly over event-driven tenofovir gel, but the difference is not statistically significant. Daily gel application came in a close third. Cranston concluded that due to these results, rectal tenofovir gel is worthy of further study. Research is already underway to expand the pipeline of rectal microbicide products in order to find the right product to move forward into an effectiveness study, said Ian McGowan (MTN), co-author of the study.
New Cure Work Discussed at CROI:
On the day before CROI officially opened, the AIDS Treatment Activists Coalition
, European AIDS Treatment Group
, Project Inform
co-sponsored a community workshop on scientific, regulatory and community engagement issues in HIV cure research, which included an update on an exciting and emerging area using bNAbs for treatment and acute infection in the FRESH (Females Rising through Education, Support, and Health) cohort in South Africa. Presentations
are posted online.
As always, please be in touch
with any questions, and we look forward working with all of you post-CROI to act on these results!